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Abstract
Background: Adipocyte fatty acid-binding protein (A-FABP) has been shown to play important roles in the development of
metabolic syndrome, diabetes, and cardiovascular diseases. In this study we investigated the possible role of A-FABP in the
development of cardiac dysfunction related to rosiglitazone treatment.
Methodology/Principal Findings: A total of 84 patients with newly diagnosed type 2 diabetes were treated with
rosiglitazone for 48 weeks. Circulating A-FABP and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were
determined at baseline and repeated at 24 and 48 weeks. After the 48-week rosiglitazone treatment period, serum levels of
both A-FABP and NT-proBNP increased progressively and significantly (P,0.01). Serum levels of A-FABP were demonstrated
to be positively correlated with gender and waist circumference both at baseline and the end of the study, and with age,
body mass index (BMI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and NT-proBNP
at 48 weeks (all P,0.05). In addition, changes in A-FABP were significantly and positively correlated with changes in NT-
proBNP (r=0.239, P=0.039). Furthermore, multiple stepwise regression analysis showed that the changes in A-FABP were
independently and positively associated with changes in NT-proBNP after adjusting for confounding factors (b=0.320,
P=0.007).
Conclusions/Significance: Rosiglitazone-mediated increase of A-FABP is closely associated with the elevation of NT-proBNP,
a well-established marker of cardiac dysfunction. The findings of our study imply that A-FABP may mediate the cross-talk
between heart and adipose tissue.
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Introduction
Adipocyte fatty acid-binding protein (A-FABP), also known as
FABP4, is a cytosolic lipid chaperone that reversibly binds with high
affinity to hydrophobic ligands, such as saturated and unsaturated
long-chain fatty acids [1]. It is predominantly expressed in mature
adipocytes and activated macrophages [2,3]. Emerging evidences
suggest that A-FABP plays an important role in lipid-mediated
biological processes, and is closely associated with obesity, diabetes,
themetabolicsyndrome, and thedevelopmentof atherosclerosis[4–
7]. Recently, the relationship between A-FABP and cardiovascular
disease has raised much attention. A genetic variant associated with
increased A-FABP mRNA expression in adipose tissue has been
reported to predict coronary artery disease in homozygous subjects
[8]. Several studies found the relationship between serum A-FABP
levels and coronary atherosclerosis [9,10]. We have recently
demonstrated that A-FABP is closely associated with the presence
and severity of coronary artery disease [11].
Thiazolidinediones (TZDs) are peroxisome proliferator activat-
ed receptor c (PPARc) agonists that specifically augment insulin
sensitivity in peripheral tissues. The cardiovascular adverse events
of rosiglitazone such as fluid retention and risk of ischaemic
cardiovascular events and heart failure during the treatment of
diabetes have been recognized [12,13]. The precise biological
mechanism responsible for the cardiovascular risk of rosiglitazone
remains uncertain. Cell-based assay has demonstrated that the
expression of A-FABP can be induced by PPARc agonists [14],
which can also increase the circulating levels of brain natriuretic
peptide (BNP) [15]. Circulating concentrations of N-terminal pro-
brain natriuretic peptide (NT-proBNP) has been proposed as a
biomarker of cardiovascular disease and in particular a marker of
heart failure, and holds promise as a tool to screen the general
population both for prevalence of underlying cardiac structural
and functional abnormalities as well as for the future development
of cardiovascular events [16,17]. Although the adverse effect of
rosiglitazone on fluid dynamics has been proposed as a probable
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unclear whether A-FABP is also involved in the PPARc agonists-
induced changes of cardiovascular function. In the present study,
we investigated the long-term effects of rosiglitazone on circulating
A-FABP and NT-proBNP levels in patients with newly diagnosed
type 2 diabetes (T2DM), and the possible role of A-FABP in the
development of cardiac dysfunction.
Methods
Ethics Statement
All subjects gave written informed consent, and the study was
approved by the ethics committee of Shanghai Jiao Tong
University Affiliated Sixth People’s Hospital and complied with
the Declaration of Helsinki.
Participants
Subjects with newly diagnosed T2DM were recruited from the
outpatient clinics of 10 academic hospitals in Shanghai. The
diagnosis of T2DM was based on 1999 World Health Organiza-
tion criteria [18]. The criteria for study inclusion and exclusion
have been described previously [19,20]. This study includes data
from 84 patients (60 men, 24 women) aged 52.668.9 years. All
patients were treated with rosiglitazone (Avandia; GlaxoSmith-
Kline, Munich, Germany) for 48 weeks which were comprised of 8
visits. Fasting plasma glucose (FPG) and 2-h postchallenge plasma
glucose (2hPG) were monitored at each visit. The initial dose of
rosiglitazone was 4 mg/d and escalated to 8 mg/d in patients who
failed to attain FPG ,7 mmol/l and/or 2hPG ,11 mmol/l.
Liver function tests were performed every 12 weeks. Lipid profile
and arginine stimulation test which was to estimate acute insulin
secretion of islet b cells were performed at baseline and repeated at
24 and 48 weeks.
Anthropometric evaluation
A complete physical examination including height, weight, waist
circumferences, and systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were performed on each subject at baseline,
24 weeks and 48 weeks after the initiation of rosiglitazone therapy.
Body mass index (BMI) was calculated as weight in kilograms
divided by squared height in meters (kg/m
2). Waist circumference
was measured midway between the lowest rib and the superior
border of iliac crest on midaxillary line.
Biochemical measurements
Blood samples were collected after an overnight fast. Arginine
stimulation tests were performed on all the patients. At time 0,
arginine hydrochloride (10% arginine hydrochloride of 50 ml,
Table 1. Clinical characteristics of study subjects.
Baseline 24 weeks 48 weeks
Waist circumference (cm) 88.267.3 87.169.0 87.468.3
BMI (kg/m
2) 25.062.9 24.863.2 24.863.0
SBP (mmHg) 128.1617.3 127.7616.7 125.7617.1
DBP (mmHg) 83.4610.0 80.769.3
* 79.469.1
*
TC (mmol/l) 5.461.2 5.561.2 5.561.2
TG (mmol/l)
{ 1.9 (1.2–2.8) 1.8 (1.3–2.5) 1.9 (1.1–2.8)
HDL-c (mmol/l) 1.260.2 1.360.3 1.360.3
*
LDL-c (mmol/l) 3.461.0 3.260.9 3.260.9
Fasting insulin (mU/l) 14.267.1 15.867.5 16.269.8
FPG (mmol/l) 8.961.8 6.360.9
* 6.561.2
*
2hPG (mmol/l) 13.563.2 8.362.5
* 8.762.1
*
HbA1c (%) 8.261.5 6.360.6
* 6.360.7
*
HOMA-IR 6.563.7 4.162.4
* 4.563.4
*
HOMA-B%
{ 72.2 (44.3–123.3) 94.2 (68.3–152.8) 91.6 (60.7–134.3)
AIR (mU/l)
{ 22.2 (12.5–36.3) 19.0 (11.1–34.6) 22.7 (11.3–39.0)
Data are mean 6 SD or median (interquartile range). AIR: acute insulin
response; BMI: body mass index; DBP, diastolic blood pressure; FPG: fasting
plasma glucose; 2hPG: 2-h postchallenge plasma glucose; HbA1c: glycated
hemoglobin A1c; HDL-c: high density lipoprotein cholesterol; HOMA-IR:
homeostasis model assessment index of insulin resistance; HOMA-B%:
homeostasis model assessment index of beta cell function; LDL-c: low density
lipoprotein cholesterol; SBP, systolic blood pressure; TC: total cholesterol;
TG: triglyceride.
{Log transformed before analysis.
*P,0.01 vs. baseline.
doi:10.1371/journal.pone.0027032.t001
Figure 1. Serum A-FABP and NT-proBNP concentrtions at
baseline and after 24 and 48 weeks of rosiglitazone therapy in
84 patients with newly diagnosed T2DM. Data are median with
interquartile range. A: Serum A-FABP levels at baseline and after 24 and
48 weeks of rosiglitazone therapy were 0.8 (0.4–1.3) ng/ml, 2.5 (1.4–3.9)
ng/ml, and 5.0 (2.7–9.7) ng/ml for all patients, 0.7 (0.3–1.2) ng/ml, 2.5
(1.4–3.8) ng/ml, and 3.9 (2.4–8.1) ng/ml for men, and 0.9 (0.7–1.5) ng/ml,
2.6 (1.7–6.4) ng/ml, and 8.0 (4.0–12.4) ng/ml for women. B: Serum NT-
proBNP levels at baseline and after 24 and 48 weeks of rosiglitazone
therapy were 11.1 (5.0–30.3) ng/l, 17.6 (7.8–37.6) ng/l, and 20.0 (9.4–
40.9) ng/l for all subjects, 9.7 (5.0–24.2) ng/l, 14.2 (5.3–32.3) ng/l, and
16.0 (6.7–30.1) ng/l for men, and 17.2 (9.0–39.2) ng/l, 30.7 (17.3–51.9)
ng/l, and 46.1 (19.4–65.7) ng/l for women. * P,0.01 versus baseline.
** P,0.001 versus baseline. # P,0.001 versus 24 weeks.
doi:10.1371/journal.pone.0027032.g001
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were drawn at times 0, 2, 4, and 6 min after injection for
glucose and insulin measurements [21]. Plasma glucose
concentrations were measured using glucose oxidase method.
Serum insulin was assayed via radioimmunoassay (Linco
Research, St Charles, MO, USA). Glycated hemoglobin A1c
(HbA1c) values were determined by high performance liquid
chromatography (Bio-Rad Laboratories, Hercules, CA, USA).
Serum lipid profiles, including total cholesterol (TC), triglycer-
ide (TG), high-density lipoprotein cholesterol (HDL-C), and
low-density lipoprotein cholesterol (LDL-C) were measured by
enzymatic procedures using an autoanalyser (Hitachi 7600–020;
Hitachi, Tokyo, Japan). NT-proBNP was assayed by chemilu-
minescence (Cobas 6000, Roche Diagnostics GmbH, Mann-
heim, Germany). A-FABP levels were assayed by sandwich
ELISA (Antibody and Immunoassay Services, the University of
Hong Kong). The intra- and inter assay variations were 4.5 and
6.7%, respectively.
Evaluation of insulin resistance (IR) and b-cell function
IR and basal insulin secretion were estimated using the
homeostasis model assessment (HOMA) index based on fasting
glucose and insulin measurements as follows: HOMA-IR= fasting
insulin (mU/l)6FPG (mmol/l)/22.5. HOMA of beta cell function
(HOMA-B%)=206fasting insulin/(FPG-3.5) [22]. The acute
insulin response (AIR) was used to examine the amount of acute
phase insulin secretion after arginine stimulation, and was
calculated as the mean insulin value of 2, 4, and 6 min minus
fasting insulin concentration.
Statistical analysis
All analyses were performed using SPSS version 13.0 (SPSS,
Chicago, IL). Data were expressed as means 6 SD for normal
distributions or median (interquartile range) for skewed variables.
Data that were not normally distributed as determined by the
Kolmogorov-Smirnov test were logarithmically transformed
before analysis. To test the effect of rosiglitazone treatment
during the examination period, we used repeated-measures
ANOVA to compare data from baseline and weeks 24 and 48,
and multiple comparisons were performed applying the Bonfer-
roni correction. Pearson’s correlation was used to evaluate the
relationships among continuous variables. Multiple stepwise
regression analysis was performed to determine the independent
parameters correlated with A-FABP, NT-proBNP, and changes
in A-FABP and NT-proBNP. P , 0.05 was considered
significant.
Results
Clinical characteristics of the patients
The demographic and biochemical characteristics of the study
subjects at baseline and after 24 and 48 weeks treatment with
rosiglitazone were summarized in Table 1. Compared to baseline,
DBP, FPG, 2hPG, HbA1c, and HOMA-IR all decreased
Table 2. Anthropometric and biochemical parameters showing significant correlations with serum A-FABP and NT-proBNP at
baseline.
A-FABP NT-proBNP
Univariate
{ Multivariate
* Univariate
{ Multivariate
#
rP b Pr Pb P
Age 0.033 0.769 0.554 ,0.001 0.421 ,0.001
Gender (women) 0.208 0.034 0.207 0.048 0.249 0.022
Waist circumference 0.203 0.039 0.038 0.729
BMI 0.205 0.062 0.345 0.020 -0.089 0.423
SBP 0.038 0.731 0.171 0.075
DBP 0.056 0.610 0.033 0.731
TC -0.028 0.803 -0.137 0.156
TG 0.134 0.176 -0.181 0.059
HDL-c -0.116 0.241 0.211 0.054
LDL-c 0.175 0.076 -0.166 0.085 -0.230 0.032
FPG -0.069 0.535 -0.195 0.078
2hPG 0.142 0.207 -0.113 0.317
Fasting insulin -0.085 0.440 -0.028 0.773
HbA1c -0.139 0.161 -0.236 0.030
HOMA-IR 0.178 0.123 -0.277 0.016 -0.252 0.019
HOMA-B% 0.045 0.672 0.061 0.599
AIR 0.089 0.367 -0.215 0.025
A-FABP 0.112 0.258
b, Standardized regression coefficients.
{Pearson correlation analyses were performed.
*A multiple stepwise regression analysis was performed. Variables included in the original model are age, gender, waist circumference, BMI, and LDL-c.
#A multiple stepwise regression analysis was performed. Variables included in the original model are age, gender, SBP, TG, HDL-c, LDL-c, FPG, HbA1c, HOMA-IR, and AIR.
doi:10.1371/journal.pone.0027032.t002
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significantly at week 48 (all P,0.01).
Serum levels of A-FABP and NT-proBNP are higher in women
than that in men at both baseline (both P,0.01) and the end of the
study (both P,0.05). As shown in Figure 1, 24 and 48 weeks after
the treatment with rosiglitazone, serum levels of A-FABP increased
progressively and significantly in both genders (all P,0.001). As
compared with week 24, A-FABP levels also significantly increased
at the study end (P,0.001). Serum NT-proBNP demonstrated
similar increasing trend, with significant higher levels at 48 weeks
for men and at both 24 and 48weeks for women compared to
baseline (all P,0.01).
Correlation analysis and multiple linear regression
analysis showing parameters related to A-FABP and NT-
proBNP
At baseline (Table 2), univariate analysis revealed significant
correlations of serum A-FABP with gender (women) and waist
circumference (both P,0.05). Serum NT-proBNP was positively
correlated with age and gender (women) (both P,0.05), and
negatively correlated with HbA1c, HOMA-IR, and AIR (all
P,0.05). On multiple stepwise regression analysis, gender
(P=0.048) and BMI (P=0.020) were independently related
to A-FABP, and age (P,0.001), LDL-c (P=0.032), and
HOMA-IR (P=0.019) were independently correlated with
NT-proBNP.
After 48 weeks of rosiglitazone therapy (Table 3), serum levels of
A-FABP were demonstrated to be positively correlated with age,
gender, waist circumference, BMI, TC, TG, LDL-c, and NT-
proBNP (all P,0.05). Serum NT-proBNP was shown to be
positively correlated with age, gender, SBP, HDL-c, and A-FABP,
and negatively correlated with BMI, FPG, fasting insulin, HOMA-
IR, and AIR (all P,0.05). On multiple stepwise regression
analysis, age (P=0.002), gender (P=0.009), BMI (P=0.023), TG
(P=0.019), and LDL-c (P=0.002) were independently and
positively related to A-FABP, whereas age (P,0.001), gender
(P=0.036), and HOMA-IR (P=0.026) were independent factors
for NT-proBNP. However, the relationship between A-FABP and
NT-proBNP was abolished after multi-adjustment.
Relationship between changes in A-FABP and NT-proBNP
versus changes in anthropometric and biochemical
parameters
As shown in Table 4, during the 48-week treatment period,
changes in A-FABP were negatively associated with changes in
HDL-c, and positively correlated with changes in waist circum-
ference and TG (all P,0.05). Changes in serum NT-proBNP were
negatively correlated with changes in fasting insulin (P=0.003).
Furthermore, changes in A-FABP were significantly and positively
correlated with changes in NT-proBNP (P=0.039). Multiple
stepwise regression analysis further showed that changes in NT-
proBNP and changes in A-FABP were independently and
Table 3. Anthropometric and biochemical parameters showing significant correlations with serum A-FABP and NT-proBNP after
the 48-week rosiglitazone treatment.
A-FABP NT-proBNP
Univariate
{ Multivariate
* Univariate
{ Multivariate
#
rP b Pr P b P
Age 0.376 ,0.001 0.312 0.002 0.587 ,0.001 0.492 ,0.001
Gender (women) 0.285 0.009 0.243 0.009 0.355 0.001 0.200 0.036
Waist circumference 0.217 0.049 -0.127 0.259
BMI 0.231 0.035 0.229 0.023 -0.231 0.038
SBP 0.171 0.125 0.227 0.043
DBP 0.161 0.147 -0.084 0.461
TC 0.480 ,0.001 0.014 0.897
TG 0.351 0.001 0.241 0.019 -0.100 0.369
HDL-c -0.068 0.539 0.281 0.011
LDL-c 0.451 ,0.001 0.303 0.002 0.021 0.850
FPG 0.051 0.663 -0.237 0.035
2hPG -0.181 0.107 -0.059 0.603
Fasting insulin 0.148 0.179 -0.394 ,0.001
HbA1c 0.077 0.493 -0.019 0.868
HOMA-IR 0.003 0.981 -0.426 ,0.001 -0.218 0.026
HOMA-B% 0.031 0.790 -0.137 0.252
AIR 0.034 0.757 -0.275 0.013
A-FABP 0.250 0.024
b, Standardized regression coefficients.
{Pearson correlation analyses were performed.
*A multiple stepwise regression analysis was performed. Variables included in the original model are age, gender, waist circumference, BMI, TC, TG, LDL-c, and
NT-proBNP.
#A multiple stepwise regression analysis was performed. Variables included in the original model are age, gender, BMI, SBP, HDL-c, FPG, fasting insulin, HOMA-IR, AIR,
and A-FABP.
doi:10.1371/journal.pone.0027032.t003
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ing factors (b=0.320, P=0.007). In addition, changes in A-FABP
and NT-proBNP were independently associated with changes in
waist circumference and BMI, respectively (both P,0.05).
Discussion
In the present study, we have shown that serum levels of both A-
FABP and NT-proBNP were increased progressively and
significantly after the treatment with rosiglitazone in a cohort of
newly diagnosed type 2 diabetic patients, and have demonstrated
for the first time that changes in serum levels of A-FABP
were independently and positively associated with changes in NT-
proBNP.
In vitro studies suggest that A-FABP is regulated by PPARc
agonists such as rosiglitazone not only in human adipocytes but
also in macrophages [14,23]. A-FABP expression is activated by
PPARc-signaling through the PPRE element present in the A-
FABP gene promoter [24]. Rosiglitazone treatment not only
caused an increase in A-FABP mRNA and protein levels in human
adipocytes but also in A-FABP secretion from adipocytes [25].
However, few clinical studies have reported the effect of
rosiglitazone on serum levels of A-FABP. In this study, in
accordance with these cell-based observations, we found serum
levels of A-FABP increased progressively with rosiglitazone
therapy in diabetic patients. An approximately 6-fold increase in
serum A-FABP levels was observed after the 48-week treatment.
Likewise, a cross-sectional study demonstrated that serum A-FABP
levels were significantly higher in TZD-treated type 2 diabetic
patients than that in control subjects. In addition, they also
reported in their subgroup analysis on 6 patients that another
PPARr agonist pioglitazone increased serum A-FABP levels
significantly after a 12-week treatment [25]. Therefore, our study
provides the clinical evidence that rosiglitazone act as an
important regulator in A-FABP production in humans.
Another novel observation of this study is the independent and
positive relationship between changes in serum levels of A-FABP
and NT-proBNP. It has been reported previously that plasma
BNP levels are increased with impaired ventricular function in the
treatment of diabetic patients with TZD [15,26]. In the present
study we found a significant increase in serum NT-proBNP levels
following rosiglitazone therapy. The precise mechanisms respon-
sible for the increase in NT-proBNP levels associated with
rosiglitazone treatment remain unclear. One probable explanation
is the result of increased cardiac wall stretch caused by volume
retention which is considered as the main adverse event of TZD
therapy. Christos Sambanis et al. reported that pioglitazone does
not alter echocardiographic parameters even though it increases
NT-proBNP after a 3 month treatment period in 44 patients with
T2DM, and speculated that it may represent a reaction to volume
overload [27]. It has been suggested that serial monitoring changes
in BNP levels over time is beneficial to potentially enable the
Table 4. Changes in anthropometric and biochemical parameters showing significant correlations with changes in serum A-FABP
and NT-proBNP during the 48-week rosiglitazone treatment.
D A-FABP D NT-proBNP
Univariate
{ Multivariate
* Univariate
{ Multivariate
#
rP b Pr Pb P
Age 0.372 0.001 0.289 0.014 0.403 ,0.001 0.240 0.044
Gender (women) 0.237 0.030 0.290 0.012 0.243 0.024
D Waist circumference 0.242 0.028 0.309 0.004 -0.099 0.403
D BMI 0.081 0.468 -0.208 0.076 -0.215 0.048
DSBP -0.169 0.129 -0.127 0.284
DDBP -0.143 0.200 -0.106 0.371
DTC 0.120 0.275 -0.173 0.138
D TG 0.217 0.047 -0.119 0.309
D HDL-c -0.290 0.007 -0.011 0.927
D LDL-c 0.045 0.685 -0.151 0.197
D FPG 0.108 0.358 -0.166 0.167
D 2hPG -0.073 0.528 -0.112 0.354
D Fasting insulin -0.032 0.776 -0.333 0.003
D HbA1c 0.069 0.543 0.041 0.735
D HOMA-IR 0.017 0.885 -0.180 0.148
D HOMA-B% -0.061 0.604 -0.221 0.074
D AIR 0.097 0.381 -0.079 0.501
D NT-proBNP 0.239 0.039 0.289 0.014
D A-FABP 0.239 0.039 0.320 0.007
D, differences between after and before treatment.
b, Standardized regression coefficients.
{Pearson correlation analyses were performed.
*A multiple stepwise regression analysis was performed. Variables included in the original model are age, gender, D waist circumference, D TG, D HDL-c, and D NT-
proBNP.
#A multiple stepwise regression analysis was performed. Variables included in the original model are age, gender, D BMI, D fasting insulin, D HOMA-B%, and D A-FABP.
doi:10.1371/journal.pone.0027032.t004
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of cardiac dysfunction before echocardiographic changes [28].
Although NT-proBNP levels of the patients during the process of
this study are within normal ranges, we could not exclude a potent
fluid retention, which may be developed as a result of rosiglitazone
therapy. In addition, A-FABP may promote the increased
secretion of NT-proBNP through its direct actions on cardiomy-
ocytes. Notably, a recent study suggested that A-FABP secreted by
human adipocytes in extracellular medium was able to directly
suppress cardiomyocyte contraction by attenuating intracellular
Ca
2+ levels [29]. Our finding on the independent association
between changes in serum A-FABP and NT-proBNP suggested an
interaction may exist between adipose tissue and heart. We
therefore speculate that the elevated circulating levels of A-FABP
released from subcutaneous and/or visceral adipose tissue in
response to rosiglitazone therapy may play an adverse role on
cardiomyocyte function, causing an increased synthesis of BNP.
Furthermore, epicardial adipose tissue has been shown to express
A-FABP and is related to the components of the metabolic
syndrome [30]. As there is no fibrous fascial layer between
epicardial adipose tissue and the underlying myocardium, A-FABP
derived from epicardial adipose tissue may also influence the
expression and secretion of BNP through direct paracrine effect.
Besides that, A-FABP may exert adverse impact on cardiac
function through aggravating the pro-inflammatory responses
[31]. However, the precise mechanism underlying the indepen-
dent association between A-FABP and NT-proBNP requires
further investigation.
Consistent with previous studies [4,5], serum levels of A-FABP
in our type 2 diabetic patients were independently associated with
lipid and parameters of adiposity such as TG, LDL-c and BMI,
especially after the 48-week rosiglitazone treatment. An indepen-
dent relationship between changes in serum A-FABP and changes
in waist circumference was also observed. It is known that A-FABP
binds fatty acids with high affinity and mediates intracellular lipid
trafficking [32]. Therefore, our findings support the role of A-
FABP as a key player of obesity-related metabolic disorders.
Interestingly, our study also demonstrated an independent and
negative relationship of serum NT-proBNP with HOMA-IR both
at baseline and the end of the study. Recently, several studies
reported the link between obesity and natriuretic peptide levels,
demonstrating an inverse relationship of BMI with BNP and NT-
proBNP concentration in subjects with and without heart failure
[33,34]. Multiple mechanisms may contribute to these inverse
associations. On the one hand, impaired synthesis and diminished
release of NT-proBNP from the heart with increasing BMI are
likely to play a role [34]. On the other hand, natriuretic peptides
also exert impact on fat cells. BNP was found to be able to
stimulate lipolysis in human fat cells through a cGMP-dependent
protein kinase signaling pathway [35]. Therefore, the negative
relationship between NT-proBNP and cardiovascular risk factors
in our study also suggests a reciprocal regulation between heart
and fat metabolism.
This study is limited by the lacking of data on echocardiogra-
phy. Therefore, we could not provide solid evidence on the change
of cardiac structure and systolic or diastolic function, as well as
their relationship with the increment of serum A-FABP. Further
prospective studies including echocardiographic evidence are
warranted to clarify whether the association between A-FABP
and NT-proBNP following rosiglitazone therapy is dependent on
the cardiovascular function.
In summary, our study provide the first evidence that changes in
serum levels of A-FABP are independently associated with changes
in serum NT-proBNP following rosiglitazone treatment. The
findings of our study suggest A-FABP may play an important role
in early cardiac dysfunction and imply that A-FABP may mediate
the cross talk between the heart and adipose tissue.
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